JP2013513586A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513586A5
JP2013513586A5 JP2012542577A JP2012542577A JP2013513586A5 JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5 JP 2012542577 A JP2012542577 A JP 2012542577A JP 2012542577 A JP2012542577 A JP 2012542577A JP 2013513586 A5 JP2013513586 A5 JP 2013513586A5
Authority
JP
Japan
Prior art keywords
composition according
composition
carbon atoms
active ingredient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513586A (ja
JP5663595B2 (ja
Filing date
Publication date
Priority claimed from EP09015423A external-priority patent/EP2335735A1/en
Application filed filed Critical
Publication of JP2013513586A publication Critical patent/JP2013513586A/ja
Publication of JP2013513586A5 publication Critical patent/JP2013513586A5/ja
Application granted granted Critical
Publication of JP5663595B2 publication Critical patent/JP5663595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542577A 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物 Active JP5663595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
EP09015423.8 2009-12-14
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014203406A Division JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2013513586A JP2013513586A (ja) 2013-04-22
JP2013513586A5 true JP2013513586A5 (https=) 2014-01-09
JP5663595B2 JP5663595B2 (ja) 2015-02-04

Family

ID=41731659

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012542577A Active JP5663595B2 (ja) 2009-12-14 2010-12-13 ドライアイ症候群の治療のための医薬組成物
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014203406A Active JP6096731B2 (ja) 2009-12-14 2014-10-01 ドライアイ症候群の治療のための医薬組成物
JP2016248533A Active JP6397472B2 (ja) 2009-12-14 2016-12-22 ドライアイ症候群の治療のための医薬組成物
JP2018163569A Pending JP2019006803A (ja) 2009-12-14 2018-08-31 ドライアイ症候群の治療のための医薬組成物
JP2018248700A Active JP6731039B2 (ja) 2009-12-14 2018-12-28 ドライアイ症候群の治療のための医薬組成物

Country Status (15)

Country Link
US (1) US8614178B2 (https=)
EP (2) EP2335735A1 (https=)
JP (5) JP5663595B2 (https=)
KR (2) KR101722039B1 (https=)
CN (1) CN102652022B (https=)
AU (1) AU2010333039B2 (https=)
BR (3) BR122020020872B1 (https=)
CA (2) CA2776860C (https=)
DK (1) DK2512515T3 (https=)
ES (1) ES2449308T3 (https=)
IN (1) IN2012DN03128A (https=)
MX (1) MX2012006720A (https=)
PL (1) PL2512515T3 (https=)
PT (1) PT2512515E (https=)
WO (1) WO2011073134A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
TR201812013T4 (tr) 2012-09-12 2018-09-21 Novaliq Gmbh Göz yikama bi̇leşi̇mleri̇.
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
ES2799185T3 (es) * 2013-03-13 2020-12-15 Santen Pharmaceutical Co Ltd Agente terapéutico para la disfunción meibomiana
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
CA2927321A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2017058774A1 (en) * 2015-09-29 2017-04-06 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
MX2018003781A (es) 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) * 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
EP3558308A1 (en) * 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
PT3399962T (pt) * 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク. mTOR阻害剤の無水組成物およびその使用方法
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3852734A1 (en) * 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
SG11202102820VA (en) * 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
CN114126580A (zh) 2019-05-24 2022-03-01 诺瓦利克有限责任公司 用于治疗眼部过敏的眼用组合物
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN120916776A (zh) * 2023-02-13 2025-11-07 诺瓦利克有限责任公司 用于眼表疾病患者的眼部手术准备的眼用组合物
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
WO2005099718A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) * 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Similar Documents

Publication Publication Date Title
JP2013513586A5 (https=)
JP2013540140A5 (https=)
JP2013518056A5 (https=)
ES2717204T3 (es) Compuestos aminoesteroideos para una aplicación tópica local para la descolonización cutáneo-mucosa de Staphylococcus aureus
JP2019529457A5 (https=)
JP2009544722A5 (https=)
JP2013511496A5 (https=)
JP2020517622A (ja) ヨウ素組成物
JP2012512907A5 (https=)
JP2010077141A5 (https=)
JP2009102342A5 (https=)
JP5805389B2 (ja) 非経口用抗菌剤
JP2011201907A5 (https=)
JP2013518036A5 (https=)
HRP20151000T1 (hr) Antivirusni spojevi
JP2014516942A5 (https=)
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
JP2013512277A5 (https=)
US20160090600A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
CO6400138A2 (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
JP2018532698A (ja) カルボキシ置換(ヘテロ)芳香環誘導体並びにその調製方法及び使用
JP2008501760A5 (https=)
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
WO2008093059A1 (en) Basic peptides and their use as combined antibacterial-antifungine agents
JP2009040767A5 (https=)